A Study of Single Dose of LP-003 in Adolescent Subjects

Exclusion Criteria

• •Allergic to LP-003 or its excipients.
• •Any serious or uncontrolled chronic disease (e.g., severe arrhythmia, ischemic heart disease, NYHA Class III/IV heart failure, severe pulmonary disease, inadequately controlled asthma, hypertension, diabetes, hypo- or hyperthyroidism) that may affect subject safety as determined by the Investigator.
• •History of severe allergic reactions.
• •Abnormal venous access, venipuncture or subcutaneous injection intolerance, history of needle or blood phobia.
• •Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m² at screening.
• •ALT or AST \> ULN and considered clinically significant by the Investigator.
• •Any other abnormal screening test result that, in the Investigator's opinion, could affect subject safety or study assessments.
• •Systemic corticosteroid therapy (intravenous, intramuscular, or oral) within 4 weeks prior to study drug administration.
• •Use of medications known to interact with epinephrine (e.g., β-blockers, ACE inhibitors, tricyclic antidepressants) within 4 weeks prior to administration.
• •Use of biologic products (e.g., omalizumab) within 6 months prior to administration.
• •Receipt vaccines within 14 days before administration or planning vaccination during the study.
• •Participation in other clinical trials within 3 months prior to screening or within 5 half-lives of investigational product discontinuation (whichever is longer).
• •Any other conditions that the Investigator considers subjects unsuitable for participation in the study.